-
Je něco špatně v tomto záznamu ?
N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors
M. Krátký, K. Jaklová, Š. Štěpánková, K. Svrčková, V. Pflégr, J. Vinšová
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články
Grantová podpora
20-19638Y
Czech Science Foundation - International
SVV260 547
Czech Ministry of Education, Youth and Sports - International
CZ.02.1.01/0.0/0.0/16_019/0000841
EFSA-CDN (Charles University) - International
- MeSH
- acetylcholinesterasa metabolismus MeSH
- benzamidy chemická syntéza chemie farmakologie MeSH
- butyrylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory chemická syntéza chemie farmakologie MeSH
- Electrophorus MeSH
- koně MeSH
- molekulární struktura MeSH
- simulace molekulového dockingu MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Development of acetyl- (AChE) and butyrylcholinesterase (BuChE) inhibitors belongs to viable strategies for the treatment of dementia and other diseases related to decrease in cholinergic neurotransmission. OBJECTIVE: That is why we designed twenty-two analogues of a dual AChEBuChE salicylanilide inhibitor, N-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide 1, to improve its potency. METHODS: We prepared N,N-disubstituted (thio)carbamates via direct acylation with (thio)carbamoyl chloride, N-n-alkyl monosubstituted carbamates using isocyanates as well as its salicylanilide core analogues. The derivatives were evaluated in vitro against AChE from electric eel and BuChE from equine serum using spectrophotometric Ellman's method. RESULTS: The compounds showed moderate inhibition of both AChE and BuChE with IC50 from 18.2 to 196.6 μmol.L-1 and 9.2 to 196.2 μmol.L-1, respectively. Importantly, based on the substitution pattern, it is possible to modulate selectivity against AChE or BuChE and some derivatives also produced a balanced inhibition. In general, the most promising analogues were N-alkyl (C2-C6) carbamates and isomers with a changed position of phenolic hydroxyl. N-[3,5-Bis(trifluoromethyl)phenyl]-3-bromo-5- hydroxybenzamide 4a was the best inhibitor of both cholinesterases. CONCLUSION: A wide range of the derivatives improved the activity of the hit 1, they were superior to carbamate drug rivastigmine against AChE and some of them also against BuChE. The most promising derivatives also fit physicochemical space and structural features for CNS drugs together with an escalated lipophilicity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020808
- 003
- CZ-PrNML
- 005
- 20210830102442.0
- 007
- ta
- 008
- 210728s2020 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1568026620666200819154722 $2 doi
- 035 __
- $a (PubMed)32814530
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Krátký, Martin $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 245 10
- $a N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors / $c M. Krátký, K. Jaklová, Š. Štěpánková, K. Svrčková, V. Pflégr, J. Vinšová
- 520 9_
- $a BACKGROUND: Development of acetyl- (AChE) and butyrylcholinesterase (BuChE) inhibitors belongs to viable strategies for the treatment of dementia and other diseases related to decrease in cholinergic neurotransmission. OBJECTIVE: That is why we designed twenty-two analogues of a dual AChEBuChE salicylanilide inhibitor, N-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide 1, to improve its potency. METHODS: We prepared N,N-disubstituted (thio)carbamates via direct acylation with (thio)carbamoyl chloride, N-n-alkyl monosubstituted carbamates using isocyanates as well as its salicylanilide core analogues. The derivatives were evaluated in vitro against AChE from electric eel and BuChE from equine serum using spectrophotometric Ellman's method. RESULTS: The compounds showed moderate inhibition of both AChE and BuChE with IC50 from 18.2 to 196.6 μmol.L-1 and 9.2 to 196.2 μmol.L-1, respectively. Importantly, based on the substitution pattern, it is possible to modulate selectivity against AChE or BuChE and some derivatives also produced a balanced inhibition. In general, the most promising analogues were N-alkyl (C2-C6) carbamates and isomers with a changed position of phenolic hydroxyl. N-[3,5-Bis(trifluoromethyl)phenyl]-3-bromo-5- hydroxybenzamide 4a was the best inhibitor of both cholinesterases. CONCLUSION: A wide range of the derivatives improved the activity of the hit 1, they were superior to carbamate drug rivastigmine against AChE and some of them also against BuChE. The most promising derivatives also fit physicochemical space and structural features for CNS drugs together with an escalated lipophilicity.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a benzamidy $x chemická syntéza $x chemie $x farmakologie $7 D001549
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a Electrophorus $7 D004593
- 650 _2
- $a koně $7 D006736
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jaklová, Karolína $u Department of Chemistry, Faculty of Science, J. E. Purkinje University, Ceske mladeze 8, 400 96 Ústi nad Labem, Czech Republic
- 700 1_
- $a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
- 700 1_
- $a Svrčková, Katarína $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
- 700 1_
- $a Pflégr, Václav $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Vinšová, Jarmila $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 773 0_
- $w MED00007896 $t Current topics in medicinal chemistry $x 1873-4294 $g Roč. 20, č. 23 (2020), s. 2094-2105
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32814530 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102442 $b ABA008
- 999 __
- $a ok $b bmc $g 1691399 $s 1141254
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 20 $c 23 $d 2094-2105 $e - $i 1873-4294 $m Current topics in medicinal chemistry $n Curr Top Med Chem $x MED00007896
- GRA __
- $a 20-19638Y $p Czech Science Foundation $2 International
- GRA __
- $a SVV260 547 $p Czech Ministry of Education, Youth and Sports $2 International
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000841 $p EFSA-CDN (Charles University) $2 International
- LZP __
- $a Pubmed-20210728